USA: 2nd Genomic & Proteomic Drug Discovery Conference

With omics based technologies, novel genes and potential candidate proteins can be quickly identified. However, the discovery of viable drug targets still remains a challenge in the genomic and proteomic field while regulatory and ethical issues continue to hinder the process of bringing drugs into the market. Meanwhile, pharmacogenomic studies remain at the forefront for developing personalized medicine.
GTC’s 2nd Genomic & Proteomic Drug Discovery Conference is a 2-day meeting to be held on May 30-31st, at the Hyatt Harborside in Boston, MA. Additionally, there will be a supplementary Clinical Sequencing Workshop to be held on May 29th. The conference will be a forum for the use of omics based methods such as next generation sequencing and mass spectrometry for biomarker discovery and the development of novel therapeutics. Technology, diagnostics and major pharmaceuticals such as Pfizer, Roche, Novartis, GlaxoSmithKline, Merck , Genzyme, Lifetechnologies, Agilent and more will meet with academic and government experts to discuss the novel applications of omics based research and its implications toward personalized medicine.

Conference Website